MaxCyte vs Seer
MaxCyte reported revenue of $33 million in fiscal 2025, 2.0 times Seer's $17 million in fiscal 2025. MaxCyte's revenue fell 14.5% in its latest year, and Seer's grew 17.0%. MaxCyte had an operating margin of -157.1%, against -470.4% at Seer. Free cash flow was −$36 million at MaxCyte and −$46 million at Seer.
Side by side
| MaxCyte | Seer | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $33M | $17M |
| Revenue growth | −14.5% | 17.0% |
| Revenue growth a year, last 5 years | 4.7% | 88.4% |
| Gross margin | 81.2% | 51.1% |
| Operating margin | −157.1% | −470.4% |
| Net margin | −135.1% | −444.0% |
| Free cash flow | −$36M | −$46M |
| Free cash flow margin | −109.5% | −278.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.5% | — |
| Last close | $1.28 | $1.39 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $120,780, sold $8,316 | sold $117,931 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MaxCyteSeer
Operating margin
Percent of revenue
MaxCyteSeer
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MaxCyteSeer